Background-Fetal tachyarrhythmia may result in low cardiac output and death. Consequently, antiarrhythmic treatment is offered in most affected pregnancies. We compared 3 drugs commonly used to control supraventricular tachycardia (SVT) and atrial flutter (AF). Methods and Results-We reviewed 159 consecutive referrals with fetal SVT (nϭ114) and AF (nϭ45). Of these, 75 fetuses with SVT and 36 with AF were treated nonrandomly with transplacental flecainide (nϭ35), sotalol (nϭ52), or digoxin (nϭ24) as a first-line agent. Prenatal treatment failure was associated with an incessant versus intermittent arrhythmia pattern (nϭ85; hazard ratio [HR]ϭ3.1; PϽ0.001) and, for SVT, with fetal hydrops (nϭ28; HRϭ1.8; Pϭ0.04). Atrial flutter had a lower rate of conversion to sinus rhythm before delivery than SVT (HRϭ2.0; Pϭ0.005).Cardioversion at 5 and 10 days occurred in 50% and 63% of treated SVT cases, respectively, but in only 25% and 41% of treated AF cases. Sotalol was associated with higher rates of prenatal AF termination than digoxin (HRϭ5.4; Pϭ0.05) or flecainide (HRϭ7.4; Pϭ0.03). If incessant AF/SVT persisted to day 5 (nϭ45), median ventricular rates declined more with flecainide (Ϫ22%) and digoxin (Ϫ13%) than with sotalol (Ϫ5%; PϽ0.001). Flecainide (HRϭ2.1; Pϭ0.02) and digoxin (HRϭ2.9; Pϭ0.01) were also associated with a higher rate of conversion of fetal SVT to a normal rhythm over time. No serious drug-related adverse events were observed, but arrhythmia-related mortality was 5%. Conclusion-Flecainide and digoxin were superior to sotalol in converting SVT to a normal rhythm and in slowing both AF and SVT to better-tolerated ventricular rates and therefore might be considered first to treat significant fetal tachyarrhythmia. (Circulation. 2011;124:1747-1754.)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.